PubRank
Search
About
Marc Salzberg
Author PubWeight™ 15.25
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
J Clin Oncol
2005
2.70
2
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.
Proc Natl Acad Sci U S A
2007
2.64
3
Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study.
Lancet Oncol
2008
1.39
4
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
J Clin Oncol
2003
1.28
5
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
J Gene Med
2003
1.27
6
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
J Thorac Oncol
2007
0.98
7
A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer.
Lung Cancer
2013
0.98
8
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
J Thorac Oncol
2008
0.97
9
Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects.
Clin Pharmacokinet
2013
0.93
10
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Cancer Chemother Pharmacol
2005
0.92
11
Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.
Eur J Cancer
2006
0.76
12
An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing.
Swiss Med Wkly
2003
0.76